Report
Thomas Vranken

Onward Medical FIRST LOOK: Entering the BCI arena

Onward announced a license agreement with the French research institute CEA for exclusive rights to Clinatec's WIMAGINE BCI. Onward already collaborated with Clinatec for several years, and now brings the technology inhouse for further development. We see the move as a solid step forward given WIMAGINE's established safety profile, long-lasting signal stability and proven compatibility with Onward's ARC-IM technology. We reiterate our € 9.3 TP and Buy rating, as we look out for the anticipated FDA approval of Onward's first device ARC-EX by YE24.
Underlying
ONWARD MEDICAL NV

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities
Thibault Leneeuw ... (+4)
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch